The European Commission has approved new indications for pembrolizumab in combination with chemotherapy in select patients with gastric or gastroesophageal adenocarcinoma and select patients with biliary tract cancer.
GUANGZHOU, China, Oct. 30, 2023 Burning Rock Biotech Limited is pleased to announce that the Company and Boehringer Ingelheim officially have signed the Master Service Agreement in the field.
Burning Rock Biotech Limited announced that the Company and Boehringer Ingelheim officially have signed the Master Service Agreement in the field of oncology companion diagnostics. This agreement.